Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. Sosei Group and Cancer Research UK announced that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ immunotherapy drug HTL0039732. HTL0039732 works by blocking […]
